Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1160)	12/20/1997 4:34:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 7041

Zonagen lie #6: Well, perhaps the word "lie" is a tad too harsh...how about "omission" or "misleading statement". I direct the reader to - again - read the first paragraph of the following press release very carefully: pslgroup.com ---------------------- THE WOODLANDS, Texas, June 24, 1996 -- Zonagen, Inc. (NASDAQ:ZONA, Pacific ZNG) announced today that it has received notification from the United States Patent and Trademark Office that the patent covering the use of VASOMAX(TM) as a treatment for erectile dysfunction (impotency) has been allowed... ----------------------- I think it would be fair to say that when Joe investor receives a phone call from a certain Texas "financial advisor" with a pitch to buy this fine, young company...and then the advisor sends him some promotional literature that includes the aforementioned press release, then Joe investor might...just might...get the impression that Zonagen developed a brand new drug and through its own efforts filed a new patent application which was subsequently approved. After all, Joe investor can be confident that this certain Texas "financial advisor" has Joe's best interst in mind. Now if only Joe investor took a little time to actually dig up the patent and read the title page: patent.womplex.ibm.com Joe then scratches his head and says, "Hey wait a minute, this patent was filed 3 years ago by some Zorgnioti guy, doesn't cover the Vasomax formulation, and Zonagen is only the assignee! Imagine that!" With a little bit more digging, Joe would have found out that the patent was paid for in stock (at much lower prices than Joe is paying). Joe would also be astonished to learn that the certain Texas "financial advisor" in our story also was paid with some cut-rate stock. What a coincidence.